Ganitumab - Biotech's 5 key attacks on pancreatic cancer

Drug: Ganitumab (AMG 479)
Company: Amgen, Takeda
Phase: Phase III
Type: Monoclonal antibody

Scoop: Amgen's late-stage pancreatic drug candidate ganitumab (AMG 479) is a monoclonal antibody designed to block a chemical signal that allows tumors to grow unchecked. The drug targets type 1 insulin-like growth factor receptor (IGF-1R), which is vital to the regulation of cell growth and survival. Amgen researchers hope that by suppressing IGF-1R they can slow the growth of pancreatic cancer tumors and increase overall survival in patients.

In a mid-stage study, patients who received AMG 479 in addition to standard pancreatic cancer therapy gemcitabine had an overall survival rate of 57% after 6 months, compared to 50% with gemcitabine alone. Seeking Alpha notes that patients in the AMG 479 arm of the study had a median overall survival rate of 8.7 months, compared to just 5.9 months on the standard therapy. Amgen initiated a Phase III study of ganitumab earlier this year. Results of the 825-patient study are due in October 2013. The drug is also in earlier stages of testing for a variety of other cancers.

"We know that insulin-like growth factors play a role in cancer development, particularly in mediating cell survival," Amgen principal scientist Pedro Beltran said in a 2009 release. "This is the first drug that specifically targets the receptor for these growth factors without cross-reacting with the closely related insulin receptor."

Amgen is partnered with Japan's Takeda on development of the drug. In 2008 the two developers inked a deal which gave Takeda exclusive rights to develop and commercialize up to 12 of Amgen's clinical stage molecules for the Japanese market; AMG 479 was included in that deal.

Ganitumab - Biotech's 5 key attacks on pancreatic cancer

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.